The Bax inhibitor 1 and two small-molecule compounds STF-083010 and 4μ8c, inhibit IRE1α RNase activity, representing potential as therapeutic candidates for NASH management [161]. The gene discussed is ERN1; the disease is metabolic dysfunction-associated steatohepatitis.